← Leaderboards
George J Brewer
University Of Michigan At Ann Arbor
$2,763,501
Attributed
$2,763,501
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $857.6K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$2,154,173 · 11
FDA$609,328 · 1
By mechanism
M01$2,154,173 · 11
R01$609,328 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Sofia Diana Merajver$3,387,621
- Susan G. Urba$225,204
- Henry Isaac Mosberg$11,490,941
- Mark E Meyerhoff$16,191,724
- Kevin G Rice$7,628,862
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectHepatolenticular DegenerationCopperDrug Screening /EvaluationZincLiver Disorder ChemotherapyMetabolism Disorder ChemotherapyClinical TrialsFemaleDrug Adverse EffectClinical Trial Phase IiiAngiogenesis InhibitorsPharmaceutical PreparationsLiverInstitutionRandomizedChelation TherapyChelating AgentsDietary SupplementsFundingComputer Retrieval Of Information On Scientific Projects DatabaseGrant
Grant awards (25)
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN PRIMARY BILIAR*$303,079
R01 · FY2007 · FD · contact PI
PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE$177,145
M01 · FY2007 · RR · contact PI
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN INITIAL HEPATIC WILSON'S DISEASE$21,013
M01 · FY2007 · RR · contact PI
PHASE III TRIAL OF TETRATHIOMOLYBDATE (TM) IN PRIMARY BILIARY CIRRHOSIS$15,591
M01 · FY2007 · RR · contact PI
PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE$460,895
M01 · FY2006 · RR · contact PI
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN PRIMARY BILIAR*$306,249
R01 · FY2006 · FD · contact PI
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN INITIAL HEPATIC WILSON'S DISEASE$85,843
M01 · FY2006 · RR · contact PI
THERAPY OF WILSON'S DISEASE WITH TETRATHIOMOLYBDATE - COMPARISON WITH TRIENTINE$4,599
M01 · FY2006 · RR · contact PI
PHASE III STUDY OF DOSE REGIMEN IN INITIAL NEUROLOGICAL WILSON'S DISEASE$383,409
M01 · FY2005 · RR
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN INITIAL HEPATIC WILSON'S DISEASE$129,690
M01 · FY2005 · RR
THERAPY OF WILSON'S DISEASE WITH TETRATHIOMOLYBDATE - COMPARISON WITH TRIENTINE$40,142
M01 · FY2005 · RR
PHASE III TRIAL OF TETRATHIOMOLYBDATE IN PRIMARY BILIAR*$0
R01 · FY2005 · FD
Phase III Study of Dose Regimen in Initial Neurological Wilson's Disease$614,531
M01 · FY2004 · RR
Phase III Trial of Tetrathiomolybdate in Initial Hepatic Wilson's Disease$169,263
M01 · FY2004 · RR
Therapy of Wilson's Disease with Tetrathiomolybdate - Comparison with Trientine$51,846
M01 · FY2004 · RR
Tetrathiomolybdate as antiangiogenesis therapy for choroidal neovascularization$0
M01 · FY2002 · RR
Severe zinc induced copper deficiency &urgent treatment with copper$0
M01 · FY2002 · RR
TREATMENT OF WILSONS DISEASE WITH ZINC$0
M01 · FY2002 · RR
THERAPY OF WILSONS DISEASE W/ TETRATHIOMOLYBDATE COMPARISON W/ TRIENTINE$0
M01 · FY2002 · RR
INITIAL THERAPY OF WILSON'S DISEASE WITH AMMONIUM TETRATHIOMOLYBDATE$0
M01 · FY2002 · RR
THERAPY OF WILSONS DISEASE W/ TETRATHIOMOLYBDATE COMPARISON W/ TRIENTINE$206
M01 · FY2000 · RR
INITIAL THERAPY OF WILSON'S DISEASE WITH AMMONIUM TETRATHIOMOLYBDATE$0
M01 · FY2000 · RR
Tetrathiomolybdate as antiangiogenesis therapy for choroidal neovascularization$0
M01 · FY2000 · RR
Severe zinc induced copper deficiency &urgent treatment with copper$0
M01 · FY2000 · RR
TREATMENT OF WILSONS DISEASE WITH ZINC$0
M01 · FY2000 · RR